Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi ...

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

TOKYO and NEW YORK, May 22, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (PFE) today announced longer-term follow-up results from ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

https://www.tipranks.com/news/the-fly/astrazeneca-reports-saphnelo-demonstrates-reduction-in-disease-activity-thefly Astellas Pharma (ALPMY) and Pfizer (PFE ...

(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma U.S. Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination with leuprolide and ...

A group of lawmakers is urging the National Institutes of Health and HHS to lower the cost of Medivation’s and Astellas Pharma’s prostate cancer drug Xtandi, according to a Reuters report. The request ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow up of ...